AMO959
AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.
Overview
AMO959 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Novartis Pharmaceuticals, in prostate cancer. Described in the registry record as a by1298 by101298 dna damage response inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a by1298 by101298 dna damage response inhibitor; the trial entries below carry the sponsor's wording.
1.AMO959 slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"AMO959" OR ABSTRACT:"AMO959" OR TITLE:"BY1298" OR ABSTRACT:"BY1298" OR TITLE:"BY101298" OR ABSTRACT:"BY101298") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AMO959, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
- TrialAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
- TreatmentSabatolimab
Shares Advanced Accelerator Applications (Novartis) and the tags pipeline, registry-only.
- TreatmentSpartalizumab
Shares Advanced Accelerator Applications (Novartis) and the tags pipeline, registry-only.
- TreatmentTNO155
Shares Advanced Accelerator Applications (Novartis) and the tags pipeline, registry-only.
- TreatmentRV001V
Shares Prostate cancer and the tags pipeline, registry-only.